Karyopharm Therapeutics Inc. KPTI

Company Overview

Karyopharm Therapeutics Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. The company operates primarily in the oncology sector and is best known for developing selective inhibitors of nuclear export (SINE) compounds that target exportin 1 (XPO1), a protein involved in transporting tumor suppressor proteins out of the cell nucleus. Karyopharm’s lead commercial product is XPOVIO (selinexor), which has received regulatory approvals in multiple hematologic cancer indications, including multiple myeloma and diffuse large B-cell lymphoma. The company generates revenue primarily from product sales, licensing arrangements, and collaboration agreements related to its oncology pipeline.

Karyopharm was founded in 2008 and is headquartered in Newton, Massachusetts. The company emerged from research focused on nuclear transport biology and advanced its proprietary SINE platform into clinical-stage development. Over time, it evolved from a research-focused biotechnology company into a commercial oncology enterprise following U.S. Food and Drug Administration approvals for selinexor. Karyopharm’s strategic positioning centers on its proprietary expertise in nuclear export inhibition and its ability to develop orally administered oncology therapies targeting difficult-to-treat cancers.